Clinical trials: Azacitidine
AML, Refractory
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options.
- Conditions
- AML, Refractory, Relapsed
- Trial name
- NCT06265545
- Testing
- Ivosidenib, Venetoclax, Gilteritinib
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
MDS
A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS
This is an open-label, phase 1b study to evaluate the safety, tolerability and preliminary efficacy of IBI188 in combination with Azacitidine in newly diagnosed higher risk MDS patients.
- Trial name
- NCT04511975
- Testing
- IBI188, Azacitidine
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Acute Myeloid Leukemia (AML)
Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia
The purpose of this study is to assess real-world effectiveness and safety of oral azacitidine in adults diagnosed with acute myeloid leukemia (AML) in Hong Kong
- Trial name
- NCT07458542
- Testing
- Azacitidine
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma, Hodgkin Disease
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
This is a phase I, prospective, open label, dose escalation study of azacitidine in combination with rituximab, vincristine, and cyclophosphamide for the treatment of refractory lymphoma.
- Conditions
- Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin
- Trial name
- NCT00901069
- Testing
- Azacitidine with rituximab, vincristine, and cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Shams Shakil
Acute Myeloid Leukemia
Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65
The purpose of this study is to find out if by giving a combination of 3 drugs the leukemia will go into complete remission (meaning the leukemia is completely gone), and to find out how long it stays away.
- Trial name
- EXJADE (NCT02341495)
- Testing
- Deferasirox, Cholecalciferol, Azacitidine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Elizabeth Henry
Myelodysplastic Syndrome (MDS)
A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
The primary objective of the study is to determine the response rate according to the International Working Group Response criteria for the combination of FF-10501-01 and azacitidine in patients previously untreated with…
- Trial name
- NCT03486353
- Testing
- FF-10501-01, Azacitidine
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Hodgkin Lymphoma
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
This is an open-label, Phase 2/3，multicenter and single-arm clinical trial of Camrelizumab plus decitabine for Anti-PD-1 treatment-naive patients with relapsed or refractory Hodgkin Lymphoma.
- Trial name
- NCT04510610
- Testing
- Camrelizumab and Decitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Adult Acute Myeloid Leukemia
Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation .
- Trial name
- NCT05262465
- Testing
- microtransplantation, HLA-mismatched donor peripheral stem cell infusion, Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 300 people
- Sponsor
- guomei
Myelodysplastic Syndrome
5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
Approved dosing schedule of azacitidine for myelodysplastic syndrome (MDS) is 75 mg/m^2/day subcutaneous for 7 consecutive days every 28 days, which is based on the data from standard chemotherapy regimen and a Phase I safety…
- Trial name
- NCT01652781
- Testing
- Azacitidine
- Where
- 3 sites in South Korea
- Volunteers
- 92 people
- Sponsor
- Seoul St. Mary's Hospital
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer
This phase I trial is studying the side effects and best dose of decitabine and valproic acid in treating patients with non-small cell lung cancer.
- Trial name
- NCT00084981
- Testing
- decitabine, valproic acid, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant
The purpose of this study is to find out if treating people who have high-risk myelodysplastic syndrome (MDS) with 5-Azacitidine (Vidaza) prior to their allogeneic hematopoietic cell transplant (HCT) is helpful in preventing…
- Trial name
- NCT00660400
- Testing
- 5-azacitidine, Allogeneic Hematopoietic Cell Transplantation (HCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Pancreatic Adenocarcinoma
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
Patients with pancreatic cancer which has stopped responding to one or more chemotherapy drugs are asked to take part in this study.
- Trial name
- NCT02847000
- Testing
- Tetrahydrouridine, Decitabine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Yogen Saunthararajah
NSCLC (Advanced Non-small Cell Lung Cancer)
Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer
There are 3 parts to this clinical trial. The goal of this clinical trial (NHT102-001) is to learn how safe NHT102 is, what dose works best, and whether it can help treat advanced non-small cell lung cancer (NSCLC) that has come…
- Trial name
- NCT07864584
- Testing
- NHT102, DryNeb
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Nob Hill Therapeutics, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML
- Trial name
- TWT-202 (NCT04730258)
- Testing
- CFI-400945, Azacitidine
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- Treadwell Therapeutics, Inc
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
This trial studies the side effects of recombinant EphB4-HSA fusion protein when given together with azacitidine or decitabine in treating patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Trial name
- NCT03146871
- Testing
- Azacitidine, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Southern California
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy
This phase I trial studies the side effects and best dose of STAT inhibitor OPB-111077 when given together with decitabine and venetoclax in treating patients with acute myeloid leukemia that does not respond to treatment…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03063944
- Testing
- STAT Inhibitor OPB-111077, Decitabine, Venetoclax
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant
This phase I trial studies the effects and safety of adding azacitidine (5-AzaC) to the standard of care (Soc) for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after being treated with…
- Trial name
- NCT01390311
- Testing
- Azacitidine, Pre-DLI Salvage Chemotherapy, Donor Leukocyte Infusion (DLI)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Washington University School of Medicine
Myelodysplastic Syndromes
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
- Trial name
- ImmBridge (NCT06918834)
- Testing
- Immediate HSCT Group, Bridging Therapy Group
- Where
- 5 sites in China
- Volunteers
- 236 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Myelodysplasia
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
This study will evaluate a new maintenance therapy with the aim of improving the outcome of patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell transplantation.
- Trial name
- AMADEUS (NCT04173533)
- Testing
- Oral azacitidine
- Where
- 20 sites in United Kingdom
- Volunteers
- 326 people
- Sponsor
- University of Birmingham
Leukemia
Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01235117
- Testing
- azacitidine, laboratory biomarker analysis
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Leeds